Automated Component Processing: Reveos and Mirasol Pathogen-Inactivation
The production instruments have more complicated interfaces than the testing equipment discussed in the previous post:
In the collection area (on-site or remote), the cvolume of the whole blood and collection time are recorded in Medinfo and based on the rules, production may only occur within specified volume and collection time. Otherwise, Medinfo will block further processing.
The ISBT unit number of the whole blood units are read by the Reveos. Only those units passing the collection criteria will proceed to separation.
In about 20 minutes, the Reveos machine will simultaneously process four units of whole blood into packed RBCs, leukodepleted plasma, buffy coat platelets, and residual buffy coat. The volumes of the RBCs, plasma, and platelets are recorded in Reveos. For the platelets, the platelet yield index is also provided.
Within Medinfo, these parameters are compared to criteria of acceptability according to the manufacturer. Volumes for the platelets and plasma must be within certain ranges to permit pooling and pathogen inactivation and additive solution. Medinfo will not permit these subsequent procedures if the values are out of range and the intermediate components will be discarded.
Here is a sample of Reveos acceptable ranges for component volumes:
E4207 – Whole Blood CPD 450 mL
< 400 mL Discard
400 – 500 mL OK
> 500 mL Discard
E5259 – Leukodepleted Packed Red Blood Cells
< 230 mL Discard
230 – 330 mL OK
> 330 mL Discard
E2807 – Platelets Concentrate 20-24°C
< 20 mL Discard
20 – 55 mL OK
> 55 mL Manual decision
E2555 – FP24: Plasma Frozen <= 24h
< 170 mL Discard
170 – 360 mL OK
> 360 mL Manual decision
All these production parameters are permanently stored in Medinfo as part of the production record of that unit. The actual location (bucket) of the whole blood unit in the Reveos is also available.
RBCs are manually leukodepleted and the final volumes recorded in Medinfo based on weight. Based on the platelet yield index, platelets are pooled and the final volume recorded. Those permissible volumes are next treated with platelet additive solution PAS and then pathogen inactivated. The acceptable volumes are based on the process used, e.g. platelets in plasma versus platelets in PAS.
How a sophisticated blood bank software like Medinfo enforces good manufacturing process at all stage of production will be a future topic.
To Be Continued: